- Home
- EDSA vs APVO Comparison
EDSA vs APVO Comparison
Compare EDSA & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDSA
- APVO
- Stock Information
- Founded
- EDSA 2015
- APVO 2016
- Country
- EDSA Canada
- APVO United States
- Employees
- EDSA N/A
- APVO N/A
- Industry
- EDSA Biotechnology: Pharmaceutical Preparations
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- EDSA Health Care
- APVO Health Care
- Exchange
- EDSA Nasdaq
- APVO Nasdaq
- Market Cap
- EDSA 6.2M
- APVO 3.3M
- IPO Year
- EDSA N/A
- APVO N/A
- Fundamental
- Price
- EDSA $2.26
- APVO $0.86
- Analyst Decision
- EDSA Strong Buy
- APVO Strong Buy
- Analyst Count
- EDSA 1
- APVO 1
- Target Price
- EDSA $21.00
- APVO $296.00
- AVG Volume (30 Days)
- EDSA 11.4K
- APVO 5.7M
- Earning Date
- EDSA 05-09-2025
- APVO 05-07-2025
- Dividend Yield
- EDSA N/A
- APVO N/A
- EPS Growth
- EDSA N/A
- APVO N/A
- EPS
- EDSA N/A
- APVO N/A
- Revenue
- EDSA N/A
- APVO N/A
- Revenue This Year
- EDSA N/A
- APVO N/A
- Revenue Next Year
- EDSA N/A
- APVO N/A
- P/E Ratio
- EDSA N/A
- APVO N/A
- Revenue Growth
- EDSA N/A
- APVO N/A
- 52 Week Low
- EDSA $1.55
- APVO $0.83
- 52 Week High
- EDSA $5.59
- APVO $51.06
- Technical
- Relative Strength Index (RSI)
- EDSA 46.91
- APVO 31.48
- Support Level
- EDSA $2.11
- APVO $0.83
- Resistance Level
- EDSA $2.34
- APVO $1.10
- Average True Range (ATR)
- EDSA 0.13
- APVO 0.45
- MACD
- EDSA -0.01
- APVO 0.02
- Stochastic Oscillator
- EDSA 40.45
- APVO 1.15
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.